Male Cancer Risk + Complete (over 40s)

The Male Cancer Risk package plus added heart-focused checks: an ECG, peripheral arterial disease test, Lipoprotein(a) and a heart disease and stroke risk assessment.

  • Doctor reviewed
  • Male
Sample
Mixed
Collection
Venous draw at local venue plus at-home self-collection kit(s)
Results in
3–8 days
Biomarkers
41
Doctor reviewed
Yes
Tests for
  • Lipoprotein (a)
  • Biometric Analysis
  • Blood Health Markers
  • Bone Health, Energy & Muscles
  • Bowel Cancer Risk (qFIT test)
  • Cholesterol & Advanced Diabetes
  • Essential Proteins and Iron
  • Heart Disease & Stroke Risk
  • Heart Rhythm (ECG test)
  • Immune System
  • Kidney Function
  • Liver Function
  • +5 more

Test specifications

Sample type
mixed
Collection method
venous draw at local venue plus at-home self-collection kit(s)
Turnaround time
3–8 days
Biomarkers tested
41
At-home test
No
Doctor reviewed
Yes
Gender focus
Male

What's tested

17 biomarkers as listed by Bluecrest Wellness, of 41 in total.

Cholesterol status

  • Lipoprotein (a)
  • Biometric Analysis
  • Blood Health Markers
  • Bone Health, Energy & Muscles
  • Bowel Cancer Risk (qFIT test)
  • Cholesterol & Advanced Diabetes
  • Essential Proteins and Iron
  • Heart Disease & Stroke Risk
  • Heart Rhythm (ECG test)
  • Immune System
  • Kidney Function
  • Liver Function
  • Lung Function Check for COPD
  • Peripheral Arterial Disease (PAD)
  • Prostate Cancer Risk (PSA)
  • Stomach Cancer Risk (H Pylori)
  • Urinalysis

About this test

Male Cancer Risk + Complete (over 40s) combines the Male Cancer Risk package, covering prostate, bowel and stomach cancer risk markers alongside liver, kidney and lung function, with the extra heart-focused tests from Bluecrest's Complete package: an ECG heart rhythm check for atrial fibrillation, a peripheral arterial disease test, a heart disease and stroke risk assessment for metabolic syndrome, and a Lipoprotein(a) test for arterial plaque risk. In total it covers 41 biomarkers.

That marker count places it in the 93rd percentile for clinical depth among the cancer screening tests we track, one of the broadest packages in that category in our data. As with the standalone Male Cancer Risk package, there is no directly comparable package to benchmark the £519 price against.

Results and follow-up score well because, as with the Male Cancer Risk package, this includes a doctor review and a private consultation, plus access to Perci Health's cancer nursing team if a cancer-risk result comes back amber or red.

Who is it for?

This suits men aged 40 and over who want the broadest single package Bluecrest offers, combining prostate and other cancer-risk screening with a heart-focused health check, and who are comfortable with a higher price for that scope. If you only want the cancer-risk element without the extra heart tests, the standalone Male Cancer Risk package covers the same cancer-risk markers for £319. Bluecrest does not recommend this package under age 40, other than for those with a strong family history of prostate cancer.

How it works

Collection is mixed: a venous blood draw at a local Bluecrest venue, at-home self-collection kits for certain markers, and in-person measurements for the ECG and peripheral arterial disease checks. Results are typically returned in around 3 to 8 days. Results are reviewed by a doctor, with a private consultation by phone or webcam, and access to Perci Health's cancer nursing support if a cancer-risk result is amber or red.

Pros & cons

Pros

  • Covers 41 biomarkers, including a PSA prostate cancer risk test and added heart checks.
  • Adds ECG, peripheral arterial disease and Lipoprotein(a) tests on top of the cancer-risk markers.
  • Includes a doctor review and private consultation, unlike most individual Bluecrest tests.
  • Access to Perci Health cancer nursing support if a cancer-risk result is amber or red.

Cons

  • At £519, it is one of Bluecrest's most expensive packages here, with no comparable package to check value against.
  • Not recommended for men under 40, other than those with a strong family history of prostate cancer.
  • Cancer-risk elements, including PSA, are not diagnostic on their own.

Our editorial score

Compare Health Test Score Broadest package for men, at a premium price
Editorial confidence: 10.0/10

For £519, this combines everything in the Male Cancer Risk package, including the PSA prostate test, with the Complete health MOT's extra heart tests, an ECG, a peripheral arterial disease check, Lipoprotein(a) and a heart disease and stroke risk assessment, across 41 biomarkers. There's no comparable package in our data to weigh the price against, but it carries the same doctor review and consultation as the Male Cancer Risk package.

Score breakdown

  • Clarity and documentation 8.0/10

    The listing publishes a detailed description, some of the biomarkers by name, a stated turnaround, clear collection options, the sample type; it does not state what the report looks like.

  • Clinical depth 10.0/10

    41 biomarkers, placing it in the 93rd percentile of cancer screening tests we track.

  • Collection convenience 7.0/10

    A finger-prick sample you take at home; with a venous or clinic option as well; results in around 8 days, slower than similar tests.

  • Results and follow-up 7.0/10

    Results are reviewed by a doctor; the provider does not describe the report format.

  • Trust signals 9.5/10

    Trustpilot 4.7 from 6,787 reviews; accredited lab (UKAS ISO 15189 own lab); CQC registered; trading 14+ years.

  • Value for money 6.0/10

    £519.00; no comparable tests to benchmark against yet.

Calculated 13 September 2026 from the facts we hold about this test and provider, using our published scoring formula. Scores are not hand-edited.

View all →

qFIT Bowel Cancer Screening Test

Priced close to the FIT test group median

A stool test using the qFIT method to measure blood in a stool sample, giving a numerical result rather than a simple positive or negative. Suited to adults wanting to check a common early indicator of possible bowel cancer risk.

  • At-home test
8.1 / 10